237 related articles for article (PubMed ID: 33031533)
1. UPLC-MS/MS-based Lipidomic Profiles Revealed Aberrant Lipids Associated with Invasiveness of Silent Corticotroph Adenoma.
Wang Z; Guo X; Wang W; Gao L; Bao X; Feng M; Lian W; Zhu H; Xing B
J Clin Endocrinol Metab; 2021 Jan; 106(1):e273-e287. PubMed ID: 33031533
[TBL] [Abstract][Full Text] [Related]
2. Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.
Langlois F; Lim DST; Yedinak CG; Cetas I; McCartney S; Cetas J; Dogan A; Fleseriu M
Pituitary; 2018 Feb; 21(1):32-40. PubMed ID: 29032459
[TBL] [Abstract][Full Text] [Related]
3. Clinical Parameters of Silent Corticotroph Adenomas With Positive and Negative Adrenocorticotropic Hormone Immunostaining: A Large Retrospective Single-Center Study of 105 Cases.
Zhang K; Shou X; Chen H; Qiao N; He W; Chen Z; Shen M; Li S; Zhao Y; Zhang Z; Li Y; Ye H; Wang Y
Front Endocrinol (Lausanne); 2020; 11():608691. PubMed ID: 33584540
[TBL] [Abstract][Full Text] [Related]
4. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes.
Cooper O; Ben-Shlomo A; Bonert V; Bannykh S; Mirocha J; Melmed S
Horm Cancer; 2010 Apr; 1(2):80-92. PubMed ID: 20717480
[TBL] [Abstract][Full Text] [Related]
5. Silent corticotroph adenomas: Emory University cohort and comparison with ACTH-negative nonfunctioning pituitary adenomas.
Ioachimescu AG; Eiland L; Chhabra VS; Mastrogianakis GM; Schniederjan MJ; Brat D; Pileggi AV; Oyesiku NM
Neurosurgery; 2012 Aug; 71(2):296-303; discussion 304. PubMed ID: 22517250
[TBL] [Abstract][Full Text] [Related]
6. The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas.
Mete O; Hayhurst C; Alahmadi H; Monsalves E; Gucer H; Gentili F; Ezzat S; Asa SL; Zadeh G
Endocr Pathol; 2013 Dec; 24(4):191-8. PubMed ID: 24091601
[TBL] [Abstract][Full Text] [Related]
7. Clinical, Laboratory, and Treatment Profiles of Silent Corticotroph Adenomas That Have Transformed to the Functional Type: A Case Series With a Literature Review.
Zheng G; Lu L; Zhu H; You H; Feng M; Liu X; Dai C; Yao Y; Wang R; Zhang H; Sun X; Lu Z
Front Endocrinol (Lausanne); 2020; 11():558593. PubMed ID: 33071973
[No Abstract] [Full Text] [Related]
8. Accuracy of microcystic aspect on T2-weighted MRI for the diagnosis of silent corticotroph adenomas.
Kasuki L; Antunes X; Coelho MCA; Lamback EB; Galvão S; Silva Camacho AH; Chimelli L; Ventura N; Gadelha MR
Clin Endocrinol (Oxf); 2020 Feb; 92(2):145-149. PubMed ID: 31773787
[TBL] [Abstract][Full Text] [Related]
9. Biochemical behaviour of an incidentally diagnosed silent corticotroph adenoma.
Benaiges D; Puig J; Lafuente J; Gimeno J; Prados M; Sagarra E; Flores-Le-Roux J
Neuro Endocrinol Lett; 2012; 33(3):290-3. PubMed ID: 22635086
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of silent corticotroph pituitary neuroendocrine tumors (PitNETs) from non-functioning PitNETs using kinetic analysis of dynamic MRI.
Amano T; Masumoto T; Watanabe D; Hoshiai S; Mori K; Sakamoto N; Kino H; Akutsu H; Nakajima T
Jpn J Radiol; 2023 Sep; 41(9):938-946. PubMed ID: 37027094
[TBL] [Abstract][Full Text] [Related]
11. Silent corticotroph adenomas.
Cooper O
Pituitary; 2015 Apr; 18(2):225-31. PubMed ID: 25534889
[TBL] [Abstract][Full Text] [Related]
12. Silent corticotroph adenomas.
Ben-Shlomo A; Cooper O
Pituitary; 2018 Apr; 21(2):183-193. PubMed ID: 29344907
[TBL] [Abstract][Full Text] [Related]
13. Clinical Parameters to Distinguish Silent Corticotroph Adenomas from Other Nonfunctioning Pituitary Adenomas.
Kim D; Ku CR; Park SH; Moon JH; Kim EH; Kim SH; Lee EJ
World Neurosurg; 2018 Jul; 115():e464-e471. PubMed ID: 29678704
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Ubiquitinomics Revealed Abnormal Ubiquitinated ATP7A Involved in Down-Regulation of ACTH in Silent Corticotroph Adenomas.
Zhao S; He Y; Wang H; Li D; Gong L; Zhang Y; Li C
Front Endocrinol (Lausanne); 2022; 13():863017. PubMed ID: 35634489
[TBL] [Abstract][Full Text] [Related]
15. Untargeted Lipidomics Reveals Specific Lipid Abnormalities in Nonfunctioning Human Pituitary Adenomas.
Hu C; Zhou Y; Feng J; Zhou S; Li C; Zhao S; Shen Y; Hong L; Xuan Q; Liu X; Li Q; Wang X; Zhang Y; Xu G
J Proteome Res; 2020 Jan; 19(1):455-463. PubMed ID: 31601105
[TBL] [Abstract][Full Text] [Related]
16. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease.
Raverot G; Wierinckx A; Jouanneau E; Auger C; Borson-Chazot F; Lachuer J; Pugeat M; Trouillas J
Eur J Endocrinol; 2010 Jul; 163(1):35-43. PubMed ID: 20385723
[TBL] [Abstract][Full Text] [Related]
17. A clinicoradiological analysis of silent corticotroph adenomas after the introduction of pituitary-specific transcription factors.
Goyal-Honavar A; Sarkar S; Asha HS; Kapoor N; Balakrishnan R; Vanjare H; Chacko G; Chacko AG
Acta Neurochir (Wien); 2021 Nov; 163(11):3143-3154. PubMed ID: 34181087
[TBL] [Abstract][Full Text] [Related]
18. Defective expression of prohormone convertase 1/3 in silent corticotroph adenoma.
Tateno T; Izumiyama H; Doi M; Akashi T; Ohno K; Hirata Y
Endocr J; 2007 Dec; 54(5):777-82. PubMed ID: 17917309
[TBL] [Abstract][Full Text] [Related]
19. Clinical profiles of silent corticotroph adenomas compared with silent gonadotroph adenomas after adopting the 2017 WHO pituitary classification system.
Jiang S; Zhu J; Feng M; Yao Y; Deng K; Xing B; Lian W; Wang R; Bao X
Pituitary; 2021 Aug; 24(4):564-573. PubMed ID: 33651318
[TBL] [Abstract][Full Text] [Related]
20. Radiomics analysis allows for precise prediction of silent corticotroph adenoma among non-functioning pituitary adenomas.
Rui W; Qiao N; Wu Y; Zhang Y; Aili A; Zhang Z; Ye H; Wang Y; Zhao Y; Yao Z
Eur Radiol; 2022 Mar; 32(3):1570-1578. PubMed ID: 34837512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
